These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1277109)

  • 1. Pelvic exenterative therapy for gynecologic malignancy: an analysis of 70 cases.
    Morley GW; Lindenauer SM
    Cancer; 1976 Jul; 38(1 SUPPL):581-6. PubMed ID: 1277109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pelvic exenteration, University of Michigan: 100 patients at 5 years.
    Morley GW; Hopkins MP; Lindenauer SM; Roberts JA
    Obstet Gynecol; 1989 Dec; 74(6):934-43. PubMed ID: 2586960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pelvic exenteration in gynecologic oncology: Experience at the Mount Sinai Center, 1975-1992.
    Dottino PR; Segna RA; Jennings TS; Mandeli JP; Konsker K; Cohen CJ
    Mt Sinai J Med; 1995 Nov; 62(6):431-5. PubMed ID: 8692157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesorectal lymph node involvement and prognostic implications at total pelvic exenteration for gynecologic malignancies.
    Mourton SM; Chi DS; Sonoda Y; Alektiar KM; Venkatraman ES; Barakat RR; Abu-Rustum NR
    Gynecol Oncol; 2006 Mar; 100(3):533-6. PubMed ID: 16226800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pelvic exenteration for recurrent gynecologic malignancy: a study of 28 consecutive patients at a single institution.
    Jäger L; Nilsson PJ; Rådestad AF
    Int J Gynecol Cancer; 2013 May; 23(4):755-62. PubMed ID: 23407096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pelvic exenteration for recurrent or persistent gynecologic malignancies: a 10-year review of the Memorial Sloan-Kettering Cancer Center experience (1972-1981).
    Lawhead RA; Clark DG; Smith DH; Pierce VK; Lewis JL
    Gynecol Oncol; 1989 Jun; 33(3):279-82. PubMed ID: 2722049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continent urinary diversion and low-rectal anastomosis in patients undergoing exenterative procedures for recurrent gynecologic malignancies.
    Husain A; Curtin J; Brown C; Chi D; Hoskins W; Poynor E; Alektiar K; Barakat R
    Gynecol Oncol; 2000 Aug; 78(2):208-11. PubMed ID: 10926804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total pelvic exenteration: the Albert Einstein College of Medicine/Montefiore Medical Center Experience (1987 to 2003).
    Goldberg GL; Sukumvanich P; Einstein MH; Smith HO; Anderson PS; Fields AL
    Gynecol Oncol; 2006 May; 101(2):261-8. PubMed ID: 16426668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pelvic Exenteration in Gynecologic Cancer: La Paz University Hospital Experience.
    Moreno-Palacios E; Diestro MD; De Santiago J; Hernández A; Zapardiel I
    Int J Gynecol Cancer; 2015 Jul; 25(6):1109-14. PubMed ID: 25853383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Exenteration of pelvic organs and its modifications].
    Gotsadze DT
    Vopr Onkol; 1997; 43(6):653-6. PubMed ID: 9479371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major complications of urinary diversion after pelvic exenteration for gynecologic malignancies: a 23-year mono-institutional experience in 124 patients.
    Houvenaeghel G; Moutardier V; Karsenty G; Bladou F; Lelong B; Buttarelli M; Delpero JR
    Gynecol Oncol; 2004 Feb; 92(2):680-3. PubMed ID: 14766266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pelvic exenteration: prognostic significance of regional lymph node metastasis.
    Rutledge FN; McGuffee VB
    Gynecol Oncol; 1987 Mar; 26(3):374-80. PubMed ID: 2435621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pelvic exenteration: surgical aspects and analysis of early and late morbidity in a series of 106 patients.
    De Wever I
    Acta Chir Belg; 2011; 111(5):273-81. PubMed ID: 22191127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pelvic exenteration. Has it a role in 1987? A six year experience.
    Shepherd JH
    Verh K Acad Geneeskd Belg; 1989; 51(1):31-44; discussion 44-6. PubMed ID: 2800684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined therapy as an alternative to exenteration for locally advanced vulvovaginal cancer. II. Results, complications, and dosimetric and surgical considerations.
    Boronow RC; Hickman BT; Reagan MT; Smith RA; Steadham RE
    Am J Clin Oncol; 1987 Apr; 10(2):171-81. PubMed ID: 3565317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pelvic exenteration in gynecologic oncology. Review.
    Franchi M; Donadello N
    Eur J Gynaecol Oncol; 1994; 15(6):469-74. PubMed ID: 7533079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pelvic exenteration as ultimate ratio for gynecologic cancers: single-center analyses of 37 cases.
    de Gregorio N; de Gregorio A; Ebner F; Friedl TWP; Huober J; Hefty R; Wittau M; Janni W; Widschwendter P
    Arch Gynecol Obstet; 2019 Jul; 300(1):161-168. PubMed ID: 31011878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choices in creating continent urostomies following pelvic exenteration for gynecologic malignancies.
    Hohenfellner R; Höckel M
    Gynecol Oncol; 2002 Apr; 85(1):227. PubMed ID: 11925154
    [No Abstract]   [Full Text] [Related]  

  • 19. Pelvic exenteration: factors associated with major surgical morbidity.
    Soper JT; Berchuck A; Creasman WT; Clarke-Pearson DL
    Gynecol Oncol; 1989 Oct; 35(1):93-8. PubMed ID: 2792911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pelvic exenteration of gynecologic malignancy: indications, and technical and reconstructive considerations.
    Lambrou NC; Pearson JM; Averette HE
    Surg Oncol Clin N Am; 2005 Apr; 14(2):289-300. PubMed ID: 15817240
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.